Holen Sie sich die Stockscreener-App
135.19
4.86%
6.26
Handel nachbörslich:
135.10
-0.09
-0.07%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$128.93
Offen:
$129.62
24-Stunden-Volumen:
1.55M
Relative Volume:
1.06
Marktkapitalisierung:
$19.82B
Einnahmen:
$9.82B
Nettoeinkommen (Verlust:
$1.48B
KGV:
13.35
EPS:
10.13
Netto-Cashflow:
$2.30B
1W Leistung:
+4.52%
1M Leistung:
+0.73%
6M Leistung:
-2.35%
1J Leistung:
-33.75%
1-Tages-Spanne:
$129.40
$135.38
1-Wochen-Bereich:
$127.00
$135.38
52-Wochen-Spanne:
$110.03
$207.59
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
135.19 | 18.77B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
660.49 | 569.45B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
174.42 | 418.62B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
201.47 | 350.91B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
121.20 | 229.50B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
82.71 | 199.90B | 63.62B | 16.41B | 14.72B | 6.49 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Why Is Biogen Stock Climbing Wednesday?Biogen (NASDAQ:BIIB) - Benzinga
Biogen’s Felzartamab Trial: A Potential Game-Changer for Kidney Transplant Treatments - TipRanks
Rituxan Market Size to 2025: Emerging Demands, Trends, - openPR.com
Biogen Asserts No Obligation to Pay $122M in Intellectual Property Royalties Following Mistrial - USA Herald
5 Revealing Analyst Questions From Biogen’s Q2 Earnings Call - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Motley Fool Asset Management LLC - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Invesco Ltd. - MarketBeat
Mizuho Securities USA LLC Reduces Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Given Average Rating of "Hold" by Analysts - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Acquires 27,734 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
LPL Financial LLC Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Aigen Investment Management LP Buys Shares of 14,365 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Ontario Teachers Pension Plan Board Buys Shares of 10,849 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Biogen Says It Owes Nothing After $122M IP Royalties Mistrial - Law360
Sector Update: Health Care - MarketScreener
Biogen CEO Sees Potential in Combining Alzheimer's, Obesity Drugs - MarketScreener
Biogen’s PREVAIL Study: A New Hope for IgA Nephropathy Treatment? - TipRanks
Biogen Sees Potential in Combining Alzheimer’s and Obesity Drugs - Bloomberg.com
Entropy Technologies LP Sells 17,087 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
National Bank of Canada FI Has $27.58 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Charles Schwab Investment Management Inc. Buys 47,956 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wolfe Research Issues Negative Estimate for Biogen Earnings - MarketBeat
Headlands Technologies LLC Cuts Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment - TipRanks
Biogen Faces Growing Pains Even As Its Pipeline Progresses - Finimize
FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More - BioSpace
Biogen, Stoke dose first patient in phase 3 Dravet syndrome trial - Investing.com Australia
Biogen and Stoke Therapeutics Announce First Patient Dosed - GlobeNewswire
Breakthrough Dravet Syndrome Drug Could Transform Treatment: Phase 3 Trial Launches - Stock Titan
Deutsche Bank AG Sells 228,518 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
White Lighthouse Investment Management Inc. Takes $291,000 Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen to invest additional $2B in North Carolina’s Research Triangle Park - MSN
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Primecap Management Co. CA - MarketBeat
iA Global Asset Management Inc. Buys 2,636 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Can Biogen Inc. be recession proofSmart Allocation Stock Ideas - thegnnews.com
Biogen Inc. (NASDAQ:BIIB) Stock Holdings Raised by Natixis Advisors LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Increases Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Koss Olinger Consulting LLC Acquires New Shares in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Will Biogen’s (BIIB) New Lecanemab Data and Earnings Shift Its Alzheimer’s Growth Narrative? - simplywall.st
Vanguard Group Inc. Buys 283,964 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Bank of Nova Scotia Sells 4,241 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Eli Lilly’s obesity pill data; This week’s Q2 highlights; Biogen’s latest reinvention; and more - Endpoints News
J. Safra Sarasin Holding AG Decreases Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Innovative Approach to SMA Treatment: ThecaFlex DRx™ System Study Update - TipRanks
Biogen’s PIERRE-PK Study: A New Approach to Nusinersen Delivery in SMA - TipRanks
Acute Ischemic Stroke Pipeline 2025: Latest FDA Approvals, - openPR.com
FY2025 EPS Estimates for Biogen Lifted by Cantor Fitzgerald - MarketBeat
Arkadios Wealth Advisors Purchases Shares of 3,354 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Research Analysts Offer Predictions for Biogen Q3 Earnings - MarketBeat
Eli Lilly And Biogen (And Eisai): Muddying The Waters In Alzheimer's Disease - Seeking Alpha
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):